s 95% SVR rate with only 12 weeks therapy in genotype 1 treatment-naives in 2 small studies with 3 HCV drugs, their potent protease ABT450 + a
NNRTI, either ABT333 or ABT072, plus ribavirin. Abbott reported a 47% SVR rate in treatment-experienced patients with the same regimen, so for these patients more potent therapy regimens will have to be put together.